Stereotactic body radiation therapy for lung metastases from soft tissue XXXX .

@entity1 @entity137 @entity242 @entity5 @entity1352 @entity1822 @entity358
PURPOSE: To appraise the role of stereotactic body radiation therapy (SBRT) in @entity1 with lung metastasis from primary soft tissue @entity242 . METHODS: Twenty-eight @entity1 (51 lesions) were analysed. All @entity1 were in good performance status (1-2 eastern cooperative oncology group (ECOG)), unsuitable for surgical resection, with controlled primary @entity5 and the number of lung metastases was    4. In a risk adaptive scheme, the dose prescription was: 30Gy/1fr, 60Gy/3fr, 60Gy/8fr and 48Gy/4fr. Treatments were performed with Volumetric Modulated Arc Therapy. Clinical outcome was evaluated by thoracic and abdominal computed tomography (CT) scan before SBRT and than every 3months. @entity137 was evaluated with Common Terminology Criteria for Adverse Events (CTCAE) scale version 4.0. RESULTS: @entity1822 (36%) and @entity1352 (25%) were the most common histologies. Five @entity1 (18%) initially presented with @entity358 , whereas 23 (82%) developed them at a median time of 51months (range 11-311months) from the initial diagnosis. The median follow-up time from initial diagnosis was 65months (5-139months) and from SBRT was 21months (2-80months). No severe @entity137 (grades III-IV) was recorded and no @entity1 required hospitalisation. The actuarial 5-years local control rate (from SBRT treatment) was 96%. Overall survival at 2 and 5years was 96.2% and 60.5%, respectively. At last follow-up 15 @entity1 (54%) were alive. All other died because of distant progression. CONCLUSIONS: SBRT provides excellent local control of @entity358 from soft tissue @entity242 (STS) and may improve survival in selected @entity1 . SBRT should be considered for all @entity1 with @entity358 ( @entity358 ) and evaluated in a multidisciplinary team.
